NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Tyler, Texas.
Часто задаваемые вопросы
В каком секторе работает NanoVibronix, Inc (NAOV)?
NanoVibronix, Inc относится к сектору Здравоохранение.
Какова текущая цена акций NanoVibronix, Inc (NAOV)?
По последним данным, цена акций NanoVibronix, Inc составляет 4,02 $, предыдущее закрытие — 4,31 $. За последнюю торговую сессию акции NanoVibronix, Inc снизились на -0,29 $, что соответствует падению на -6,73%.
Выплачивает ли NanoVibronix, Inc (NAOV) дивиденды?
Нет, NanoVibronix, Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у NanoVibronix, Inc (NAOV)?
У компании NanoVibronix, Inc бета 2.059, что свидетельствует о крайне высокой волатильности по сравнению с рынком
